European Notebook: Price Cuts Planned In France; IPO Window Thrown Open; European Big Pharmas Pursue Major Deals
Increased optimism about economic growth in Europe has been followed by IPOs becoming more common among the region’s biotech companies; there’s a speculation frenzy about M&A; and with European parliamentary elections in May, further regulatory and legislative changes are likely later in the year.
You may also be interested in...
Europe’s top scientific advisory panel, the Committee for Medicinal Products for Human Use, recommended a new long-acting beta-interferon in MS, a highly pure recombinant Factor VIII, and a new combination eye-drop for glaucoma, but confirmed its previous rejections of Novartis’s heart failure therapy, Teva’s oral MS medicine and AB Science’s pancreatic cancer product.
Actavis global R&D exec G. Frederick Wilkinson joins Impax as president and CEO; FDA veteran Shaw Chen moves to Polaris. On the government side, Senate HELP Cmte. Is slated to review Sylvia Burwell’s nomination for HHS secretary and Michael Hash is retiring from the department. More personnel announcements in this month’s column.
Not inspired by its clinical effectiveness, NICE has said it will not recommend Roche's “over-priced” Kadcyla for breast cancer.